Finanzen von Revelation Biosciences Inc (REVB)REVBRevelation Biosciences Inc

Evaluating the bottom line, Revelation Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -276.43%, provide a clear picture of how effectively REVB converts its operational activities into shareholder value.

In the context of the broader market, REVB competes directly with industry leaders such as GRI and APVO. With a market capitalization of $4.10M, it holds a significant position in the sector. When comparing efficiency, REVB's gross margin of N/A stands against GRI's N/A and APVO's N/A. Such benchmarking helps identify whether Revelation Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has reported consistent net losses, with the latest being -$8.69 million for Q1 2026 and a forward P/E of 0.8875, indicating potential undervaluation but also ongoing financial struggles.